Post

New research · Ophthalmology
Japanese journal of ophthalmology · 14h
StudyJapanese journal of ophthalmology · 2026

Real-world effectiveness and safety of a fixed-dose combination of 0.4% ripasudil and 0.1% brimonidine in the management of uveitic glaucoma.

Sentaro Kusuhara, Wataru Matsumiya, Sotaro Mori … Makoto Nakamura
Read paper
OphthalmologyStudy

Most eyes with uveitic glaucoma had meaningful pressure reduction on RBFC by 12 months

Real-world effectiveness and safety of a fixed-dose combination of 0.4% ripasudil and 0.1% brimonidine in the management of uveitic glaucoma.

Sentaro Kusuhara … Makoto Nakamura
Japanese journal of ophthalmology · 2026
Purpose

To evaluate the real-world use, treatment outcomes, and tolerability of the fixed-dose combination of ripasudil 0.4% and brimonidine 0.1% (RBFC) eye drops in patients with uveitic glaucoma (uveitic glaucoma).

Methods

Single-center retrospective case series.

n = 39 eyes
64%
Results
64%
in most eyes, eye pressure dropped enough to count as meaningful improvement
n = 39 eyes
More results

The median IOP significantly decreased from 19 mmHg at baseline to 14 mmHg at 12 months (p < 0.001), while the median glaucoma drug score showed no significant change, from 3 at baseline to 4 at 12 months (p = 0.562).

A positive correlation was observed between the duration of uveitic glaucoma and the change in IOP at 12 months (rho = 0.539, p < 0.01).

More results

In the subgroup analysis restricted to eyes switched from ripasudil plus brimonidine eye drops to RBFC, IOP showed a decreasing trend (p = 0.057).

No drug-related adverse events were observed, except for transient conjunctival hyperemia.

“
Conclusion

This real-world study in patients with uveitic glaucoma showed that RBFC achieves effective IOP control while reducing treatment burden, with good tolerability, supporting its continued use in uveitic glaucoma management.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving